BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23356486)

  • 1. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for chronic lymphocytic leukemia.
    Robak T
    Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide and chronic lymphocytic leukemia.
    González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
    Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging immunological drugs for chronic lymphocytic leukemia.
    Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Wiernik PH
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
    Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
    Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
    Miller KC; Musial L; Whitworth A; Chanan-Khan A
    Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
    Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
    Molica S
    Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
    Desai M; Newberry KJ; Romaguera J; Zhang L; Ou Z; Wang M
    J Hematol Oncol; 2013 Aug; 6():55. PubMed ID: 23915913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide and thalidomide in the treatment of chronic pain.
    Asher C; Furnish T
    Expert Opin Drug Saf; 2013 May; 12(3):367-74. PubMed ID: 23442012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.